In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors

Coskuner E., Cevik I., Ozkan A., DİLLİOĞLUGİL Ö., Akdas A.

INTERNATIONAL UROLOGY AND NEPHROLOGY, cilt.44, sa.3, ss.793-798, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 3
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s11255-012-0144-x
  • Dergi Adı: INTERNATIONAL UROLOGY AND NEPHROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.793-798
  • Anahtar Kelimeler: NMP22, Urine marker, Bladder cancer, Upper urinary tract tumor, TCC, SUPERFICIAL BLADDER-CANCER, NUCLEAR-MATRIX PROTEIN, CARE PROTEOMIC ASSAY, UROTHELIAL CANCER, NATURAL-HISTORY, RENAL PELVIS, RISK-FACTORS, IN-SITU, SURVEILLANCE, CYTOLOGY
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Two percent of the bladder non-muscle-invasive (NMI) transitional cell carcinomas (TCC) are associated with upper urinary tract (UUT) TCC. We evaluated the role of nuclear matrix protein-22 (NMP-22) (BladderChek(A (R))) test in the diagnosis of lower urinary tract and UUT-TCC.